Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein

Blood

Volumn 90, Issue 1, 1997, Pages 346-353

  Gati, Wendy P ^a   Paterson, Alan R P ^a   Larratt, Loree M ^a   Turner, A Robert ^a   Belch, Andrew R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FLUORESCEIN;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CYTOTOXICITY TEST; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL;

EID: 0030971066     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.1.346     Document Type: Article

References (36)

1. Chabner BA: Cytidine analogues, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy (ed 2). Philadelphia, PA, Lippincott-Raven, 1996, p 213
2. Bryan JH, Henderson ES, Leventhal BG: Cytosine arabinoside and 6-thioguanine in refractory acute lymphocytic leukemia. Cancer 33:539, 1974
3. Smith CL, Pilarski LM, Egerton ML, Wiley JS: Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood 74:2038, 1989
4. Jamieson GP, Snook MB, Bradley TR, Bertoncello I, Wiley JS: Transport and metabolism of 1-β-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells. Cancer Res 49:309, 1989
5. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ: Pharmacologically directed araC therapy for refractory leukemia. Semin Oncol 12:20, 1985
6. Kufe DW, Major PP, Egan EM, Beardsley GP: Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 255:8997, 1980
7. Sirotnak FM, Chello PL, Dorick DM, Montgomery JA: Specificity of systems mediating transport of adenosine, 9-β-D-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells. Cancer Res 43:104, 1983
8. Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024, 1988
9. White JC, Rathmell JP, Capizzi RL: Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest 79:380, 1987
10. Alessi-Severini S, Gati WP, Belch AR, Paterson ARP: Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia 9:1674, 1995
11. Belt JA, Marina NM, Phelps DA, Crawford CR: Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 33:235, 1993
12. Cass CE: Nucleoside transport, in Georgopapadakou N (ed): Drug Transport in Antimicrobial Therapy and Anticancer Therapy. New York, NY, Dekker, 1995, p 403
13. +-linked transport of nucleoside analogs in leukemia cells from patients. Proc Am Assoc Cancer Res 34:14, 1993
14. Cass CE, Gaudette LA, Paterson ARP: Mediated transport of nucleosides in human erythrocytes: Specific binding of the inhibitor nitrobenzylthioinosine to nucleoside transport sites in the erythrocyte membrane. Biochem Biophys Acta 345:1, 1974
15. Paterson ARP, Jakobs ES, Harley ER, Cass CE, Robins MJ: Inhibitors of nucleoside transport as probes and drugs, in Cheng Y-C, Goz B, Minkoff M (eds): Development of Target-Oriented Anticancer Drugs. New York, NY, Raven, 1983, p 41
16. Jarvis SM, Young JD: Photoaffinity labelling of nucleoside transport peptides. Pharmacol Ther 32:339, 1987
17. Wiley JS, Smith CL, Jamieson GP: Transport of 2′-deoxycoformycin in human leukemia and lymphoma cells. Biochem Pharmacol 42:708, 1991
18. Wiley JS, Jones SP, Sawyer WH, Paterson ARP: Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 69:479, 1982
19. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR: Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 75:632, 1985
20. Rustum YM, Raymakers RAP: 1-β-Arabinofuranosylcytosine in therapy of leukemia: Preclinical and clinical overview. Pharmacol Ther 56:307, 1992
21. Agbanyo FR, Vijakalakshmi D, Craik JD, Gati WP, McAdam DP, Asakura J, Robins MJ, Paterson ARP, Cass CE: SAENTA, a novel ligand with high affinity for polypeptides associated with nucleoside transport: Partial purification of the nitrobenzylthioinosine-binding protein of pig erythrocytes by affinity chromatography. Biochem J 270:605, 1990
22. Wiley JS, Brocklebank AM, Snook MB, Jamieson GP, Sawyer WH, Craik JD, Cass CE, Robins MJ, McAdam DP, Paterson ARP: A new fluorescent probe for the equilibrative inhibitor-sensitive nucleoside transporter. Biochem J 273:667, 1991
23. Jamieson GP, Brocklebank AM, Snook MB, Sawyer WH, Buolamwini JK, Paterson ARP, Wiley JS: Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells. Cytometry 14:32, 1993
24. 6-(4-nitrobenzyl)-5′-thioadenosine): Flow cytometry probes for the es nucleoside transporter elements of the plasma membrane. Nucleosides and Nucleotides 13:737, 1994
25. Wiley JS, Cebon JS, Jamieson GP, Szer J, Gibson J, Woodruff RK, McKendrick JJ, Sheridan WP, Biggs JC, Snook MB, Brocklebank AM, Railings MC, Paterson ARP: Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter. Leukemia 8:181, 1994
26. Gati WP, Paterson ARP, Belch AR: Use of SAENTA-fluorescein in a flow cytometric assay of cellular es nucleoside transporter site abundance, a correlate of chemosensitivity to cytarabine in acute myeloid leukemia cells. Proc Am Assoc Cancer Res 37:405, 1996 (abstr)
27. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589, 1988
28. Sargent JM, Taylor CG: Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 60:206, 1989
29. Wang C, Curtis JE, Minden MD, McCulloch EA: Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3:264, 1989
30. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE: Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522, 1965
31. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55, 1983
32. Cass CE, King KM, Montano JT, Janowska-Wieczorek A: A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). Cancer Res 52:5879, 1992
33. Dagnino L, Bennett LL Jr, Paterson ARP: Sodium-dependent nucleoside transport in mouse leukemia L1210 cells. J Biol Chem 266:6308, 1991
34. Tattersall MHN, Ganeshaguru K, Hoffbrand AV: Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br J Haematol 27:39, 1974
35. Steuart CD, Burke PJ: Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol 233:109, 1971
36. Canadian Leukemia Study Group: A randomized trial on the efficacy of non-cross resistant, consolidation therapy versus high dose cytosine arabinoside consolidation chemotherapy following sequential response-adapted induction treatment for adult acute myelogenous leukemia. Sponsored by Pharmacia Inc, 1996